Free Trial

Phreesia (PHR) Stock Forecast & Price Target

Phreesia logo
$24.34 -0.52 (-2.09%)
(As of 02:51 PM ET)

Phreesia - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
11

Based on 12 Wall Street analysts who have issued ratings for Phreesia in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a hold rating, and 11 have given a buy rating for PHR.

Consensus Price Target

$29.33
20.51% Upside
According to the 12 analysts' twelve-month price targets for Phreesia, the average price target is $29.33. The highest price target for PHR is $34.00, while the lowest price target for PHR is $23.00. The average price target represents a forecasted upside of 20.51% from the current price of $24.34.
Get the Latest News and Ratings for PHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Phreesia and its competitors.

Sign Up

PHR Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$29.33$29.42$29.42$34.31
Forecasted Upside20.51% Upside56.43% Upside23.86% Upside42.95% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

PHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Phreesia Stock vs. The Competition

TypePhreesiaMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside17.95% Upside28,497.71% Upside12.06% Upside
News Sentiment Rating
Neutral News

See Recent PHR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Truist Financial
2 of 5 stars
 Boost TargetBuy ➝ Buy$31.00 ➝ $34.00+40.79%
12/11/2024Robert W. Baird
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$34.00 ➝ $30.00+24.22%
12/10/2024JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Outperform$30.00 ➝ $30.00+31.93%
12/10/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00+34.07%
9/27/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$23.00 ➝ $23.00+2.09%
9/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$27.00 ➝ $28.00+17.60%
9/5/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00 ➝ $34.00+44.07%
9/5/2024DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Jellison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00+33.78%
7/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$27.00 ➝ $25.00+32.77%
5/31/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00+52.76%
3/15/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$25.00 ➝ $30.00+32.45%
1/3/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$29.00+26.36%
9/12/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$43.00 ➝ $40.00+82.98%
9/7/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
9/7/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$40.00 ➝ $37.00+21.87%
3/29/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$35.00 ➝ $40.00+28.66%
1/5/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$34.00 ➝ $39.00+23.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:10 PM ET.


PHR Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Phreesia is $29.33, with a high forecast of $34.00 and a low forecast of $23.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There is currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHR shares.

According to analysts, Phreesia's stock has a predicted upside of 20.51% based on their 12-month stock forecasts.

Phreesia has been rated by research analysts at JMP Securities, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Truist Financial in the past 90 days.

Analysts like Phreesia more than other "medical" companies. The consensus rating score for Phreesia is 2.92 while the average consensus rating score for "medical" companies is 2.81. Learn more on how PHR compares to other companies.


This page (NYSE:PHR) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners